Cytek Biosciences, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
A Schedule 13G filing confirms significant beneficial ownership stakes in Cytek Biosciences, Inc. by several entities and an individual.
NASDAQ
Boston Partners has disclosed beneficial ownership of 5.9% of Cytek Biosciences, Inc. common stock as of June 30, 2026.
NASDAQ
Millennium Management LLC and affiliated entities have reported a 6.1% beneficial ownership stake in Cytek Biosciences, Inc.
NASDAQ
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly filed a Schedule 13G, reporting beneficial ownership of 5.2% of Cytek Biosciences, Inc. common stock.
NASDAQ
The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Cytek Biosciences Inc. following an internal realignment.
NASDAQ
Topline Capital Management, LLC, along with Collin McBirney and Topline Capital Partners, LP, reported a 5.3% beneficial ownership stake in Cytek Biosciences, Inc.
NASDAQ
Brown Capital Management, LLC has filed an Amendment No. 3 to Schedule 13G, disclosing a 3.9% beneficial ownership stake in Cytek Biosciences, Inc.
NASDAQ
The Vanguard Group has reported a 6.13% passive beneficial ownership stake in Cytek Biosciences Inc., holding 7,765,138 shares of common stock as of June 30, 2025.
NASDAQ
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 13.1% beneficial ownership stake in Cytek Biosciences, Inc. as of June 30, 2025.
NASDAQ
Brown Capital Management, LLC has filed an amended Schedule 13G, reporting a 5.89% beneficial ownership stake in Cytek Biosciences, Inc. as of March 31, 2025.
NASDAQ
The Vanguard Group has filed an amended Schedule 13G, reporting a 7.51% passive beneficial ownership stake in Cytek Biosciences Inc. as of March 31, 2025.
NASDAQ
SCHEDULE 13G/A: RA Capital Management Divests Entire Stake in Cytek Biosciences, Filing Amended Schedule 13G
RA Capital Management, L.P. and its affiliates have filed an amended Schedule 13G, indicating they no longer hold any beneficial ownership in Cytek Biosciences, Inc. as of December 31, 2024.
NASDAQ
SCHEDULE 13G/A: BlackRock Discloses 14.3% Stake in Cytek Biosciences, Inc.
BlackRock, Inc. has filed an updated Schedule 13G, revealing a beneficial ownership of 14.3% in Cytek Biosciences, Inc. as of December 31, 2024.